Published:
Lutronic Inc. Announces FDA Clearance of Its Spectra VRM III Q-Switched Nd:Yag Laser System for Treating a Broad Spectrum of Dermatological and Aesthetic Conditions
PRINCETON JUNCTION, N.J., May 23 /PRNewswire/ -- Lutronic, one of the
world's leading developers and manufacturers of medical laser systems,
announced today that it has received FDA clearance to market its Spectra VRM
III. This dual pulse Q-Switched Nd:Yag laser is the feature-rich successor to
the Spectra VRM II. The laser produces 4 wavelengths (1064 nm, 532 nm, 585
nm, 650 nm) in Q-switched nanosecond pulse. It is specifically designed to
treat a wide array of dermatological and aesthetic conditions, including
dermal and epidermal pigmented lesions, multicolor tattoos, melasma, and
active acne. It further enables laser toning, and non-ablative photo-acoustic
skin rejuvenation techniques.
The laser incorporates a dual pulse mode, which enables it to produce very
short and quasi-long microsecond pulses. There are numerous advantages which
result from the unique pulse characteristics not found in other lasers
including extreme high peak power and a flat-top beam profile. "The VRM III
is extremely effective for the treatment of melasma. I have been achieving
near 100% clearance on melasma treatment therapy. This is very impressive
because melasma is traditionally thought to be treatment resistant. Further,
the VRM has also been highly effective for the treatment of Post-Inflammatory
Hyperpigmentation that may result as adverse side affects from other lasers or
IPL treatments," explains Dr. Sooil Chun, the clinical professor of Yonsei
University. The company states that further scientific works are being
conducted for this treatment in an effort to collect additional empirical data
for peer reviewed studies.
As tattoo removal is becoming one of the fastest-growing treatment groups,
the 4 wavelength option offered by the VRM III laser enables treatment of a
wide range of colors. The laser's flat-top beam profile provides increased
patient comfort and reduced pinpoint bleeding, resulting in fewer side effects
and significantly faster healing. The fine control of the 532 nm wavelength
feature assures that epidermal lesions are treated with measurably less
potential for PIH.
With an installed base of over 2000 VRM series units globally, the new VRM
III is proving to be the workhorse system of choice for laser clinics around
the world.
About Lutronic
Lutronic is one of the world's leading developers and manufacturers of
medical laser systems serving the clinical dermatological and aesthetic
communities. With over a decade of award-winning technology design that
includes its Spectra line of products and its unparalleled MOSAIC Systems, the
company is committed to delivering innovative, highly effective, and painless
laser solutions. Strategically headquartered inPrinceton Junction, NJ (on
the Route 1 corridor betweenNew York City andPhiladelphia), Lutronic Inc.
maintains an extensive national network of distributors, including MedEdge,
Elite Medical, and Aesthetic Technologies ofFlorida. In addition, Lutronic
Inc. offers an impressive service department featuring experienced laser
engineers who provide the highest level of service and support to physicians
across the US. Manufacturing medical laser systems for markets inEurope and
Asia, parent Lutronic Co. Ltd. is based inSeoul, South Korea and delivers
product to over 40 countries. To learn more about the Spectra VRM III, please
visit http://www.lutronic.com.
Contact:
Ken Reich
Director, Marketing & Public Relations
Lutronic Inc.
Phone: 609 275-1565 x302 or 888 588-7644
Fax: 609 275-3800
Email: kreich@lutronic.com
This release was issued through eReleases(TM). For more information,
visit http://www.ereleases.com.
SOURCE Lutronic Inc.
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: ,HEA,MTC,HOU,FDA,PDT,WOM,NJ-Lutronic-Announces
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
